Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States

Liposomal irinotecan (nal-IRI) is a topoisomerase inhibitor proven to improve survival in metastatic pancreatic cancer (mPC). This study describes real-world characteristics of patients treated with nal-IRI for mPC. METHODS: Patients 18 years or older diagnosed with stage IV mPC and treated with nal...

Descripción completa

Detalles Bibliográficos
Autores principales: Barzi, Afsaneh, Miksad, Rebecca, Surinach, Andy, Corvino, Frank A., Wang, Siqi, Torres, Aracelis Z., Mamlouk, Khalid, Pulgar, Sonia, Valderrama, Adriana, Bekaii-Saab, Tanios, Ahn, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028474/
https://www.ncbi.nlm.nih.gov/pubmed/32011529
http://dx.doi.org/10.1097/MPA.0000000000001479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028474/
https://www.ncbi.nlm.nih.gov/pubmed/32011529
http://dx.doi.org/10.1097/MPA.0000000000001479

Ejemplares similares